Skip to main content

Advertisement

ADVERTISEMENT

First Report

Vibegron Proves Effective as Oral Therapy for Patients With Overactive Bladder
First Report
04/12/2021
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with...
04/12/2021
First Report Managed Care

Advertisement

Per the results of an indirect treatment comparison, researchers found that dupilumab is associated with lower severe asthma exacerbation rates than patients treated with anti-IL-5s and o...
“While this dataset is still maturing, in this as-observed interim analysis of a real-world study, dupilumab demonstrated early and sustained improvement in AD flares, symptoms, and disea...
First Report
10/23/2020
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, according to the Lymphoma Research Foundation, and worldwide, accounting for about 22% of newly diagnosed cases of B-cell NHL in...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, according to the Lymphoma Research Foundation, and worldwide, accounting for about 22% of newly diagnosed cases of B-cell NHL in...
Diffuse large B-cell lymphoma...
10/23/2020
First Report Managed Care

Advertisement

A recent study shows successful reduction of signs, symptoms, and severity of atopic dermatitis based on real-world patient data.
First Report
08/31/2020
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
08/31/2020
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was...
08/31/2020
First Report Managed Care

Advertisement

Recent data showing high persistence rates for dupilumab therapy in patients with atopic dermatitis suggest that the treatment is well-tolerated and effective.
“In this analysis, emicizumab-kxwh therapy was associated with a decrease in the cost of HEM medications and cost and utilization of medical services,” explained researchers.

Advertisement